Marco Quarta is the co-founder and CEO of Rubedo Life Science, a startup that develops drugs that target aging. Their lead program is a senolytic prodrug that targets senescent cells in a targeted manner.
Matt Scholz is a co-founder of Oisin Biotechnologies, a longevity startup that is developing a proteome-lipid nanoparticle gene therapy platform. Their lead program is a senolytic gene therapy to target senescent cells.